437 related articles for article (PubMed ID: 20661178)
21. A Serological Epidemiological Survey of Antibodies against 4 HPV Subtypes in Uygur Women in Xinjiang.
Husaiyin S; Han L; Mamat H; Husaiyin K; Wang L; Niyazi M
Jpn J Infect Dis; 2016 Jul; 69(4):273-8. PubMed ID: 26255734
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a phase II, double-blind, randomized controlled trial at month 7.
Konno R; Dobbelaere KO; Godeaux OO; Tamura S; Yoshikawa H
Int J Gynecol Cancer; 2009 Jul; 19(5):905-11. PubMed ID: 19574783
[TBL] [Abstract][Full Text] [Related]
23. Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16-64 years in Puerto Rico.
Ortiz AP; Tortolero-Luna G; Romaguera J; Pérez CM; González D; Muñoz C; González L; Marrero E; Suárez E; Palefsky JM; Panicker G; Unger ER
Papillomavirus Res; 2018 Jun; 5():109-113. PubMed ID: 29555601
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.
Kreimer AR; Sampson JN; Porras C; Schiller JT; Kemp T; Herrero R; Wagner S; Boland J; Schussler J; Lowy DR; Chanock S; Roberson D; Sierra MS; Tsang SH; Schiffman M; Rodriguez AC; Cortes B; Gail MH; Hildesheim A; Gonzalez P; Pinto LA;
J Natl Cancer Inst; 2020 Oct; 112(10):1038-1046. PubMed ID: 32091594
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
[TBL] [Abstract][Full Text] [Related]
26. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.
Safaeian M; Kemp TJ; Pan DY; Porras C; Rodriguez AC; Schiffman M; Cortes B; Katki H; Wacholder S; Schiller JT; Gonzalez P; Penrose K; Lowy DR; Quint W; van Doorn LJ; Herrero R; Hildesheim A; Pinto LA
Hum Vaccin Immunother; 2013 Jul; 9(7):1399-406. PubMed ID: 23571174
[TBL] [Abstract][Full Text] [Related]
27. Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer.
Combes JD; Pawlita M; Waterboer T; Hammouda D; Rajkumar T; Vanhems P; Snijders P; Herrero R; Franceschi S; Clifford G
Int J Cancer; 2014 Nov; 135(10):2453-61. PubMed ID: 24729277
[TBL] [Abstract][Full Text] [Related]
28. Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.
Lang Kuhs KA; Porras C; Schiller JT; Rodriguez AC; Schiffman M; Gonzalez P; Wacholder S; Ghosh A; Li Y; Lowy DR; Kreimer AR; Poncelet S; Schussler J; Quint W; van Doorn LJ; Sherman ME; Sidawy M; Herrero R; Hildesheim A; Safaeian M;
Am J Epidemiol; 2014 Sep; 180(6):599-607. PubMed ID: 25139208
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
Toft L; Storgaard M; Müller M; Sehr P; Bonde J; Tolstrup M; Østergaard L; Søgaard OS
J Infect Dis; 2014 Apr; 209(8):1165-73. PubMed ID: 24273179
[TBL] [Abstract][Full Text] [Related]
30. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and uninfected women from Brazil.
Nicol AF; Grinsztejn B; Friedman RK; Veloso VG; Cunha CB; Georg I; Pilotto JH; Moreira RI; Castro CA; Silver B; Viscidi RP
J Clin Virol; 2013 Jun; 57(2):147-51. PubMed ID: 23490398
[TBL] [Abstract][Full Text] [Related]
31. Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
Woestenberg PJ; Bogaards JA; King AJ; Leussink S; van der Sande MA; Hoebe CJ; van Benthem BH;
Int J Cancer; 2019 Jun; 144(11):2718-2727. PubMed ID: 30426502
[TBL] [Abstract][Full Text] [Related]
32. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected women from South Africa, Brazil and Botswana.
Firnhaber C; Evans D; Friedman-Khalili R; Willliams S; Michelow P; Matlhagela K; Wester C; Grinsztejn B; Lockman S
J Clin Virol; 2011 Nov; 52(3):265-8. PubMed ID: 21908233
[TBL] [Abstract][Full Text] [Related]
33. Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations.
Nonnenmacher B; Kruger Kjaer S; Svare EI; Scott JD; Hubbert NL; van den Brule AJ; Kirnbauer R; Walboomers JM; Lowy DR; Schiller JT
Int J Cancer; 1996 Dec; 68(6):704-9. PubMed ID: 8980170
[TBL] [Abstract][Full Text] [Related]
34. Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.
Brotherton JML; Tabrizi SN; Phillips S; Pyman J; Cornall AM; Lambie N; Anderson L; Cummings M; Payton D; Scurry JP; Newman M; Sharma R; Saville M; Garland SM
Int J Cancer; 2017 Oct; 141(8):1576-1584. PubMed ID: 28677147
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.
Lang Kuhs KA; Gonzalez P; Struijk L; Castro F; Hildesheim A; van Doorn LJ; Rodriguez AC; Schiffman M; Quint W; Lowy DR; Porras C; Delvecchio C; Katki HA; Jimenez S; Safaeian M; Schiller J; Solomon D; Wacholder S; Herrero R; Kreimer AR;
J Infect Dis; 2013 Nov; 208(10):1643-52. PubMed ID: 24014882
[TBL] [Abstract][Full Text] [Related]
36. Correlation between viral load, multiplicity of infection, and persistence of HPV16 and HPV18 infection in a Dutch cohort of young women.
van der Weele P; van Logchem E; Wolffs P; van den Broek I; Feltkamp M; de Melker H; Meijer CJ; Boot H; King AJ
J Clin Virol; 2016 Oct; 83():6-11. PubMed ID: 27522635
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.
Heijstek MW; Scherpenisse M; Groot N; Tacke C; Schepp RM; Buisman AM; Berbers GA; van der Klis FR; Wulffraat NM
Ann Rheum Dis; 2014 Aug; 73(8):1500-7. PubMed ID: 23723319
[TBL] [Abstract][Full Text] [Related]
38. Incidence and predictors of human papillomavirus-6, -11, -16, and -18 infection in young norwegian women.
Kim S; Arduino JM; Roberts CC; Marsico M; Liaw KL; Skjeldestad FE
Sex Transm Dis; 2011 Jul; 38(7):587-97. PubMed ID: 21301390
[TBL] [Abstract][Full Text] [Related]
39. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
40. HPV16 and HPV18 seropositivity and DNA detection among men who have sex with men: a cross-sectional study conducted in a sexual health clinic in London.
King EM; Mesher D; Sonnenberg P; Linley E; Panwar K; Beddows S; Soldan K; Borrow R; Jit M; Gilson R
Sex Transm Infect; 2021 Aug; 97(5):382-386. PubMed ID: 33361466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
